Oppenheimer raised the firm’s price target on TransMedics to $125 from $105 and keeps an Outperform rating on the shares. The firm cites the company’s Q1 beat and raised FY24 guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: